Biocon makes Biocon Biologics wholly-owned subsidiary via share swap

Fund Raising View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹414.20

prior close

₹416.15

announcement price

After-mkt

timing

Nifty Midcap 150market+0.4%+0.7% vs market

Pharmaceuticals peers, median of 165sector+0.8%+0.3% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Midcap 150 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.8

15m

-0.7

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1+0.4+0.7+0.8+0.3

Next day

+0.9+0.6+0.3+0.3+0.6

+1.2+1.1+0.1+0.8+0.4

+3.3+0.9+2.4+1.2+2.1

+2.4+1.3+1.1+0.6+1.7

-2.0+1.0-3.0+0.2-2.2

-1.9+0.8-2.6+0.7-2.5

15d

+6.4+2.2+4.2+1.7+4.6

+2.8+1.6+1.3-0.5+3.4

-0.5+3.8-4.3+3.0-3.5

-10.6-3.6-7.0+3.3-13.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon acquired 1.15 crore equity shares of Biocon Biologics Limited (BBL) from 127 selling shareholders in exchange for 87.86 lakh Biocon equity shares at about Rs 376.41 per share. This share swap makes BBL a wholly-owned subsidiary of Biocon. Shareholder approval was obtained via postal ballot on June 7, 2026. Paid-up equity capital rises from Rs 810.45 crore to Rs 814.85 crore. No cash outflow for the company.

Likely market impact

BBL becomes a wholly-owned subsidiary. Minor equity dilution around 0.5%. No cash outflow for Biocon.